Stockreport

Immuron Plans Phase 2 Trial for IMM-529 following FDA review

Immuron Limited - American Depositary Shares  (IMRN) 
US:NASDAQ Investor Relations: immuron.com/investor-centre/business-overview
PDF Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) [Read more]